Obsidian Therapeutics Inc.

Obsidian Therapeutics Inc.

OBX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$500.97M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Obsidian Therapeutics Inc.Obsidian Therapeutics Inc.0.1-18%--
$37.00

Target Price by Analysts

203% upsideObsidian Therapeutics Target Price DetailsTarget Price
$0.59

Current Fair Value

95.2% downside

Overvalued by 95.2% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$500.97 Million
Enterprise Value$438.52 Million
Earnings per Share$-1.63
Beta2.64
Outstanding Shares41,029,574

Return

Return on Equity17.76%ROE
Return on Assets16.71%
Return on Invested Capital-26.60%

Valuation & Multiples

P/E Ratio0.08P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio1.74Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.58
Enterprise Value to Net Income7
Total Debt to Enterprise-0.08
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS
-$1.23
Est. -$0.52
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
April 1, 2027
EPS Estimate
-$1.19
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Obsidian Therapeutics Inc.

87 employees
CEO: Madan Jagasia

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE...

Obsidian Therapeutics Insider Information FAQ

Stockcircle tracks 2 top investors with a current 13F position in Obsidian Therapeutics. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 2 top investors increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.